Patient Guide to Tumor Markers

Similar documents
Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?

A23: Oncologic Disease- Tumor Markers

Tumor Markers. What are tumor markers? How are tumor markers used? Screening and early detection of cancer

Carbohydrate antigen 19 9 (CA 19 9) (serum, plasma)

4/15/2013. bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o. anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma

Co-pay assistance organizations offering assistance

Definitions. Carcinoma. Sarcoma Any cancer of connective tissue, e.g. muscle, fat, bone, lymphatic vessels.

Adams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS

TUMOUR MARKERS : AN OVERVIEW

Amylase and Lipase Tests

Index. F Factor VIII-related antigen, see VWF FactorXIIIa, for dermatofibroma, HT, see Serotonin

PCA3 DETECTION TEST FOR PROSTATE CANCER DO YOU KNOW YOUR RISK OF HAVING CANCER?

San Luis Dermatology & Laser Clinic, Inc.

1. What is the prostate-specific antigen (PSA) test?

Protein electrophoresis is used to categorize globulins into the following four categories:

NEOPLASMS C00 D49. Presented by Jan Halloran CCS

Understanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS. foundationforwomenscancer.org

PATIENT REGISTRATION

Frequently Asked Questions About Ovarian Cancer

.org. Metastatic Bone Disease. Description

Open the Flood Gates Urinary Obstruction and Kidney Stones. Dr. Jeffrey Rosenberg Dr. Emilio Lastarria Dr. Richard Kasulke

LIVER CANCER AND TUMOURS

Closed Sub-TOI: L Life - Other Co Tr Num: BANRD-01 State Status: Approved-Closed

and The Hidden Tumor Orly & Mira Barak Tumor Markers DiaSorin

88 percent of heart attack victims under the age of 65 are able to return to their usual work. 1. solutions GROUP CRITICAL ILLNESS INSURANCE

Cancer is the leading cause of death for Canadians aged 35 to 64 and is also the leading cause of critical illness claims in Canada.

DATA CAPTURE FORM LIFE INSURANCE

AUBURN DERMATOLOGY PATIENT DEMOGRAPHIC (Please print legibly)

Number. Source: Vital Records, M CDPH

Laparoscopic Surgery of the Colon and Rectum (Large Intestine) A Simple Guide to Help Answer Your Questions

Medical Surgical Nursing (Elsevier)

MEDICAL HISTORY AND SCREENING FORM

GUIDE. Prepare for Your Phone Interview and Medical Exam.

Neuroendocrine Tumors

THYROID CANCER. I. Introduction

List of Qualifying Conditions

Patient Interview Form

Group Critical Illness Insurance

Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers

New strategies in anticancer therapy

Immunohistochemical differentiation of metastatic tumours

NICE guideline Published: 23 June 2015 nice.org.uk/guidance/ng12

dedicated to curing BREAST CANCER

Limited Pay Policy (L-222B) - Underwriting Guidelines

SOUTH TAMPA MULTIPLE SCLEROSIS CENTER

Diagnosis and Prognosis of Pancreatic Cancer

Carcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in

Patient Information. Name: Social Security Number: Birth date: Address: Phone #: House: Cell: Work: Primary Care Physician: Address:

SOUTH PALM CARDIOVASCULAR ASSOCIATES, INC. CHARLES L. HARRING, M.D. NEW PATIENT INFORMATION FORM. Patient Name: Home Address:

Policy Wording. Together, all the way.

Fulfilling the Promise

Abnormal Uterine Bleeding FAQ Sheet

Blood-Based Cancer Diagnostics

Group Critical Illness Insurance Provides lump-sum cash benefits that can help with daily expenses

Report series: General cancer information

Medical Matters Action Checklists

Kate O Hanlan, M. D. F. A. C. O. G., F. A. C. S.

Group Critical Illness Insurance Provides lump-sum cash benefits that can help with daily expenses

Group Benefits Evidence of Insurability for Comprehensive Optional Critical Illness Insurance

First Name. Profession. Weight lbs. Weight 1 year ago lbs. Min. Adult Weight lbs. at age Maximum Weight lbs. at age

Employee Critical Illness Option

Alpha-fetoprotein

BREAST HEALTH HISTORY FORM

Kidney Cancer OVERVIEW

Hepatitis C. Laboratory Tests and Hepatitis C

Calais Dermatology Associates

Assessment of tumor markers in patients with chronic renal failure

Male New Patient Package

Early Prostate Cancer: Questions and Answers. Key Points

The PSA Test for Prostate Cancer Screening:

why? 75 percent The percentage of healthy individuals over age 40 who will become critically ill at some time in the future. 3

A Source of Hard- to- Find Pa3ents and Caregivers For Researchers. Peter Ziedins

Introduction: Tumor Swelling / new growth / mass. Two types of growth disorders: Non-Neoplastic. Secondary / adaptation due to other cause.

ELEMENTS FOR A PUBLIC SUMMARY. Overview of disease epidemiology. Summary of treatment benefits

Us TOO University Presents: Understanding Diagnostic Testing

National Medical Policy

THINGS TO BE AWARE OF ABOUT PROSTATE AND LUNG CANCER. Lawrence Lackey Jr., M.D. Internal Medicine 6001 W. Outer Dr. Ste 114

Integrated Medical Services (IMS) New Patient Registration Sheet

Examples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening.

WOMENCARE A Healthy Woman is a Powerful Woman (407) Birth Control Pills

Progressive Care Insurance for life A NEW TYPE OF INSURANCE

Financial protection in case of a critical illness diagnosis Voluntary Plans

Live carefree knowing our coverage will be there to help during a critical illness.

Frozen Section Diagnosis

Pancreatic Cancer. The Killer that must be discovered early. Dr Alfred Kow Wei Chieh

Blood in the urine (hematuria)

Albumin. Prothrombin time. Total protein

CHAPTER 2. Neoplasms (C00-D49) March MVP Health Care, Inc.

HEALTH NEWS PROSTATE CANCER THE PROSTATE

Practical Effusion Cytology

Male Patient Questionnaire & History

Transcription:

Patient Guide to Tumor Markers A tumor marker is a substance that is produced by the body in response to cancer, or is produced by the cancer itself. Some of these markers are specific to one cancer, while others are seen in several types of cancer. These markers are generally used to evaluate the patient's response to treatment or to monitor for recurrence (return of the cancer after treatment). There are non-cancerous conditions that can cause markers to be elevated, so these must also be considered when interpreting the test results. Tumor markers can be used in conjunction with other tests (scans, biopsies, etc.) to help diagnose a patient who has symptoms suspicious for cancer. Some markers can help physicians to determine prognosis and treatment. Ideally, markers could be used as a screening tool for the general public. The goal of a screening test is to diagnose cancer early, when it is the most treatable and before it has had a chance to grow and spread. So far, the only tumor marker to gain some acceptance as a screening tool is the Prostate Specific Antigen (PSA) for prostate cancer, though this has its share of controversy. Other markers are either not specific enough (too many false positives - a positive result, when no cancer is actually present - leading to expensive, anxiety producing and unnecessary follow-up testing), or they are not elevated early enough in the life of the cancer, and therefore the cancer cannot be detected any earlier than when symptoms begin to appear. Keep in mind that some substances used as markers are produced naturally in the body, and a "normal" level is not always zero. Tumor markers are not elevated in all cases of the cancers they are used for, and they are not helpful in all patients. For instance, carcinoembryonic antigen (CEA) is used to detect colon cancer recurrence, yet it is only produced in 70-80% of colon cancer cases. In addition, only 25% of cases that are limited to the colon (early stages) have elevated CEA, so it cannot always detect colon cancer in its early stages, when cure rates are best. The bottom line is, tumor markers can be very helpful in following response to treatment and recurrence, but they cannot replace physical examination, evaluation of symptoms, and radiologic studies (CT scan, MRI, PET, etc.). The following is a table of the most commonly used tumor markers, the cancers they can be present with, non-cancerous conditions that can elevate them, and the range of normal results. In cases where the half-life is listed, this should be considered when checking levels. For example, the PSA half-life is 2-3 days, so if the level were checked the day after surgical removal of the prostate, it would still be elevated. If the level were checked a week later, the result should be zero, or very close to zero, if no prostate tissue remains. Tumor Marker Cancers Associated With Elevated Results Non-Cancerous Reasons for Elevated Levels "Normal" Results

Blood test (blood serum marker), except where noted. (**) indicates the most common association, if one exists Different labs may have different high/low values Germ cell cancers of ovaries AFP Alpha-fetoprotein & testes** (Non-seminomatous, particularly embryonal and yolk sac, testicular cancers). Some primary liver cancers Pregnancy (clears after birth), liver disease (hepatitis, cirrhosis, toxic liver injury), inflammatory bowel disease Low levels present in both men & non-pregnant women (0-15 IU/ml); generally results >400 are caused by cancer (Half-life 4-6 days) (hepatocellular) Bence-Jones Proteins or Monoclonal Immunoglobulins (blood Multiple Myeloma** Waldenstrom's macroglobulinemia, chronic lymphocytic leukemia Amyloidosis Generally, a value of 0.03-0.05 mg/ml is significant for early disease test) Multiple myeloma**, chronic lymphocytic leukemia (CLL), B2M Beta-2-Microglobulin and some lymphomas (including Waldenstrom s Kidney disease, hepatitis < 2.5 mg/l macroglobulinemia) BTA Bladder Tumor Antigen Bladder cancer**, cancer of kidney or ureters Invasive procedure or infection of bladder or urinary tract None normally detected CA 15-3 Cancer Antigen 15-3 or Carbohydrate Antigen 15-3 Breast** (often not elevated in early stages of breast cancer), lung, ovarian, endometrial, bladder, gastrointestinal Liver disease (cirrhosis, hepatitis), lupus, sarcoid, tuberculosis, non-cancerous breast lesions < 31 U/ml (30% of patients have an elevated CA 15-3 for 30-90 days after treatment, so wait 2-3 months after starting new treatment to check) Pancreatitis, ulcerative CA 19-9 Cancer Antigen 19-9 or Carbohydrate Antigen 19-9 Pancreas** and colorectal, liver, stomach and biliary tree cancers colitis, inflammatory bowel disease, inflammation or blockage of the bile duct, thyroid disease, rheumatic < 37 U/ml is normal > 120 U/ml is generally caused by tumor arthritis

Pregnancy, menstruation, endometriosis, ovarian cysts, CA 125 Cancer Antigen 125 or Carbohydrate Antigen 125 Ovarian cancer** breast, colorectal, uterine, cervical, pancreas, liver, lung fibroids, pelvic inflammatory disease, pancreatitis, cirrhosis, hepatitis, peritonitis, pleural effusion, 0-35 U/ml following surgery or paracentesis < 40 U/ml Generally, levels > Breast** (best used to detect 100 U/ml signify cancer (30% CA 27.29 recurrence or metastasis). Ovarian cysts, liver and of patients have elevated CA Cancer Antigen 27.29 or Colon, gastric, liver, lung, kidney disorders, 27.29 for 30-90 days after Carbohydrate Antigen 27.29 pancreatic, ovarian, prostate non-cancerous (benign) treatment, so wait 2-3 cancers breast problems months after starting new treatment to check) Chronic renal insufficiency, Calcitonin Medullary thyroid cancer** Chronic use of Proton-pump inhibitors (medications given to reduce stomach acid) <8.5 pg/ml for men < 5.0 pg/ml for women Colorectal cancers ** Breast, Cigarette smoking, CEA Carcinoembryonic Antigen lung, gastric, pancreatic, bladder, kidney, thyroid, head & neck, cervical, ovarian, liver, lymphoma, melanoma pancreatitis, hepatitis, inflammatory bowel disease, peptic ulcer disease, hypothyroidism, cirrhosis, COPD, biliary obstruction <2.5 ng/ml in non-smokers <5 ng/ml in smokers Generally, > 100 signifies metastatic cancer Chromogranin A Neuroendocrine Tumors**, carcinoid tumors, neuroblastoma, and small cell lung cancer Proton-pump inhibitors (medications given to reduce stomach acid) Normal varies on how tested, but typically < 39 ng/l is normal Cytokeratin Fragment 21-1 Lung, urologic, (Blood Test) gastrointestinal, and Lung disease 0.05-2.90 ng/ml gynecologic cancers

HCG Human Chorionic Gonadotrophin Or Beta-HCG, B-HCG Germ cell, testicular cancers**, gestational trophoblastic neoplasia Pregnancy, marijuana use, hypogonadism (testicular failure), cirrhosis, inflammatory bowel disease, duodenal ulcers In men: < 2.5 U/ml In non-pregnant women: < 5.0 U/ml Celiac & tropical sprue, Whipple's disease, dietary: 5-HIAA walnuts, pecans, bananas, 5-Hydroxy-Indol Acetic Acid (24 hour urine collection) Carcinoid tumors avocados, eggplants, pineapples, plums & Normal 6-10 mg over 24 hours tomatoes; medications: acetaminophen, aspirin and guaifenesin Hepatitis, MI (heart attack), stroke, anemia (pernicious & LDH Lactic Dehydrogenase Lymphoma, melanoma, acute leukemia, seminoma (germ cell tumors) thalassemia), muscular dystrophy, certain medications (narcotics, Normal values are 100-333 u/l aspirin, anesthetics, alcohol), muscle injury Proton pump inhibitor NSE Neuron-specific Enolase Small cell lung cancer**, neuroblastoma treatment, hemolytic anemia, hepatic failure, end stage renal failure, brain injury, Normal < 9 ug/l seizure, stroke NMP 22 Bladder cancer** BPH (benign prostatic hypertrophy), prostatitis Normal < 10 U/ml PAP Prostatic Acid Phosphatase Metastatic prostate cancer** Myeloma, lung cancer, osteogenic sarcoma Prostatitis, Gaucher's disease, osteoporosis, cirrhosis, hyperparathyroidism, Normal : 0.5 to 1.9 u/l prostatic hypertrophy BPH (benign prostatic hypertrophy), nodular PSA Prostate Specific Antigen Prostate** prostatic hyperplasia, prostatitis, prostate trauma/ Normal < 4 ng/ml (half life 2-3 days) inflammation, ejaculation

Powered by TCPDF (www.tcpdf.org) Tg Thyroglobulin Thyroid Cancer Anti-thyroglobulin antibodies < 33 ng/ml; if entire thyroid removed < 2 ng/ml Urine Catecholamines: VMA Vanillylmandelic Acid (24 hour collection of urine; it is a catecholamine metabolite) Neuroblastoma** Pheochromocytoma, ganglioneuroma, rhabdomyosarcoma, PNET Dietary intake (bananas, vanilla, tea, coffee, ice cream, chocolate), medications (tetracyclines, methyldopa, MAOIs) 8 35 mmols over 24 hours HVA Homovanillic Acid (24 hour collection of urine; it is a catecholamine Neuroblastoma** Same as VMA, in addition: psychosis, major depression, dopamine (a medication) Up to 40 mmols over 24 hours metabolite)